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ABSTRACT 
We present a case of severe interstitial pneumonitis, mild
polyarthritis and polymyositis, and Raynaud's syndrome with
the presence of anti-Jo-1 antibodies, which had been diag-
nosed as anti-synthetase syndrome. The presence, however,
of anti-Ro/SSA antibodies led us to understand that we were
dealing here with a more severe form of interstitial lung dis-
ease. The patient was treated for acute respiratory failure but
he showed resistance to glucocorticoids and cyclosporine.
Thus, he was treated with infusions of anti-CD20 therapy 
(rituximab): his clinical conditions improved very rapidly and
a significant decrease in the activity of pulmonary disease
was detected using high-resolution computerized tomogra-
phy (HRCT) of the thorax and pulmonary function tests.
Keywords: Acute respiratory failure, immunology, interstitial
lung disease, rituximab.
RIASSUNTO 
Presentiamo un caso di grave interstiziopatia polmonare, po-
liartrite e polimiosite di grado lieve e sindrome di Raynaud in
presenza di anticorpi anti-Jo-1, diagnosticata come sindrome
anti-sintetasi. Tuttavia la presenza di anticorpi anti-Ro/SSA ci
ha fatto comprendere che eravamo di fronte ad una forma di
interstiziopatia polmonare di maggiore gravità. Il paziente è
stato trattato per insufficienza respiratoria acuta, ma ha evi-
denziato resistenza agli steroidi e alla ciclosporina. È stato
perciò intrapreso un trattamento anti-CD20 per via infusiva
(rituximab): le condizioni cliniche sono rapidamente migliora-
te e alla TC torace ad alta risoluzione ed alla spirometria sono
apparsi evidenti i segni della riduzione di attività della pato-
logia polmonare. 
Parole chiave: Immunologia, insufficienza respiratoria acuta,
interstiziopatia polmonare, rituximab.
INTRODUCTION
The anti-synthetase syndrome (ASS) is a subgroup of
idiopathic inflammatory muscle disease. Its charac-
teristics are interstitial lung disease, myositis, poly -
arthritis, mechanic's hand, Raynaud's syndrome
and the presence of antisynthetase antibodies (anti-
Jo-1). Interstitial lung disease (ILD) is the major de-
terminant of morbidity and mortality in the anti-syn-
thetase syndrome (ASS).
Here we report a case of ASS with pulmonary in-
volvement, successfully treated with rituximab.
Case report 
The case involves a 58-year old Caucasian male, a
farmer up until the age of 45 and thereafter em-
ployed as a clerk. At the age of 40 the patient began
experiencing fever and asthenia following pro-
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8 longed, strenuous activity. The patient reported suf-
fering moderate muscle weakness and pain in the
previous 4 years, with painful synovitis of both
hands, Raynaud’s phenomenon and episodic fever.
In the last year a dry cough and weight loss were al-
so experienced. The patient had been a heavy
smoker (10-15 cigarettes/day) but had quit smoking
completely one year prior to his admission to our
hospital. His medical history was unremarkable and
he was not taking any kind of pharmaceutical treat-
ment.
The patient was referred to our hospital (time 0) due
to a 2 month history of rapidly worsening dyspnea,
experienced after only mild exertion, and to the
persistence and worsening of his dry cough. Two
months prior, he had been diagnosed with inter -
stitial lung disease and was treated with low doses
of corticosteroids (prednisone) and N-acetylcys-
teine for a short period (15 days), but with no im-
provement of symptoms. On admission to our hos-
pital, the patient was also suffering asthenia of the
upper and lower limbs, persistent fever and muscle
pain, which he had been experiencing for the past
4 years.
Over both lungs, diffused fine crackles were heard.
Blood gas analysis showed desaturation with low
PaO2 and PaCO2, while high resolution computer-
ized tomography (HRCT) scan showed a significant
worsening of the pulmonary fibrosis with areas of
honeycomb and ground glass opacities (Figure 1). 
The phenomenon of Reynaud was also present.
Serology revealed positive anti-Jo-1 antibodies with
increased inflammatory markers. The pulmonary
function test showed marked restrictive syndrome
(FEV1 = 50% pred.; FVC = 45% pred.; TLC = 65%
pred.) with severe reduction of DLCO (32% pred.).
Capillaroscopy pointed out nonspecific capillaro-
scopic abnormalities: non-homogeneous morphol-
ogy and distribution of capillaries which were
coiled; large and irregular hemosiderin deposition
due to hemorrhage; fragmentation of the blood col-
umn with formation of plasma gaps and a granular
aspect of the cells (Figure 2).
Electromyography showed myopathic injury associ-
ated with signs of low grade chronic nerve damage
without denervation in the lumbar-sacral root distri-
bution. The echocardiogram underlined mild pul-
monary hypertension (35 mm Hg). The patient was
unable to perform a 6-minute walking test (6MWT). 
Based on the data collected, the patient was diag-
nosed with anti-synthetase syndrome, classified as a
rare inflammatory autoimmune disease.
A high dose of steroid and immune suppression
therapy was quickly begun (methylprednisolone i.v.
2 mg/Kg/die and azathioprine 50 mg/die) which ap-
peared to result in an initial decrease of the pa-
tient’s symptoms, although not objectively verifi-
able, but with functional respiratory deterioration
(reduction of DLCO) and apparent worsening of the
radiological features. 
Treatment with cyclosporin at 5 mg/Kg was then be-
gun; however, a progressive functional and sympto-
matic worsening was observed (the patient was un-
FIGURE 1: HIGH-RESOLUTION CHEST CT SCAN SHOWING
PULMONARY FIBROSIS WITH AREAS OF HONEYCOMB AND
GROUND GLASS OPACITIES PARTICULARLY IN THE DORSO-
BASAL AREAS
FIGURE 2: CAPILLAROSCOPY SHOWING A NONSPECIFIC
PATTERN OF ABNORMALITIES AND NON-HOMOGENEITY IN
CAPILLARY LENGTH AND LOOP SIZE
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able to walk a few meters). Therefore, based on data
in the medical literature, it was decided to proceed
with the rituximab (Mabthera®: monoclonal anti-
body anti-CD20) treatment. According to the proto-
col, the treatment would involve a dosage of 1,000
mg i.v. administered twice in the course of 15 days.
A second cycle would be repeated 6 months later. 
Already the day following the first administration of
the drug (time 1), the patient began showing mild
but progressive reduction of the dyspnea and in-
creased exercise tolerance. After 10 days, the pa-
tient was discharged from hospital based on the sig-
nificant improvement of his respiratory functions.
The second dose of rituximab was administered, as
planned, after 2 weeks. Blood samples taken to
evaluate the eventual reduction of the antibody 
anti-Jo-1 showed, however, no change in the re-
sults. A thorax HRCT was repeated resulting in a
definite regression of ground glass attenuation and
stabilization of fibrotic changes (Figure 3).
The DLCO test increased its value to 52% pred.;
blood gas analysis, performed without oxygen sup-
port, showed improvement of blood gases (PaO2
78.5 mm Hg and PaCO2 30 mm Hg) (time 2). 
A second treatment course with rituximab (1,000
mg infusion with an interval of 14 days) was admin-
istered without side effects six months after the first
line therapy (time 3).
Following the first cycle of rituximab therapy, the
patient showed clinical improvement with an in-
crease in muscle strength and a decreased need of
oxygen. After the second infusion of rituximab, six
months later, the patient’s condition was markedly
improved and he was now able to resume normal
daily activities without difficulty (time 4).
The last medical examination was carried out in
December 2010, some fourteen months after the
first cycle of treatment with rituximab and seven
months after the second (time 5). The patient ap-
peared in good condition, asymptomatic for dys -
pnea, cough, fever and muscle fatigue, as in previ-
ous visits. He underwent the anti-Jo-1 test, the value
of which was reduced compared to the previous
(123); the CO diffusion test (DLCO) also improved,
with a rate of 52%, and CT of the chest, initially in
the supine position, showed the presence of
ground-glass opacity in basal areas of the lung and
then in the prone position where ground-glass areas
were significantly reduced and the lung was almost
completely ventilated (Figure 6). The results of other
tests, already normal in the previous controls, were
virtually unchanged. Given the continuing good
condition of the patient and continuing stability of
the improvements achieved, it was not considered
necessary to carry out a further administration of rit-
uximab. 
During the follow up time (Table I, Figure 5), the
clinical evaluation of the pulmonary functional test
(PFR) with DLCO and 6MWT and HRCT of the tho-
rax showed a remarkable improvement of all func-
tional parameters and radiographic imaging.
Nevertheless anti Jo-1 antibodies remained elevated
even in the absence of any disease activity. 
CONCLUSION
The advent of rituximab has undoubtedly generated
considerable hope for the treatment of many dis-
eases with immune pathogenesis. The treatment of
interstitial pneumonia associated with anti-syn-
thetase syndrome has not been standardized and, it
should be noted, some forms of pulmonary diseases
seem to be corticosteroid-resistant. In this case
study of anti-synthetase syndrome in which the 
interstitial lung disease was persistent and acute
and corticosteroid resistant, treatment with ritux-
imab proved effective and successful, in line with
published reports. These observations emphasize
the need for additional studies to assess the optimal
regimen of rituximab for the treatment of interstitial
pneumonia associated with anti-synthetase syn-
drome, to determine the initial dose, the dosing in-
terval, the number of cycles and the need for any
additional associated therapy. 
In fact, as was observed in the case described
above, the highly positive results on HRCT (Figure
5) and the improvement in the patient’s functional
performances after the second infusion, suggest that
a third cycle of rituximab repeated after another 6
months, could prove even more effective, even
though the administration of a third cycle is not in-
dicated in any research literature. 
Unfortunately, studies conducted to date and de-
FIGURE 3: HIGH RESOLUTION CHEST CT SCAN SHOWING
REGRESSION OF GROUND GLASS ATTENUATION AND






























8 FIGURE 4: GRAPHS OF PARAMETERS EVALUATED BEFORE, DURING AND AFTER TREATMENT WITH RITUXIMAB




Lung function test FVC




TABLE I: SERIAL MEASUREMENTS BEFORE, DURING AND AFTER TREATMENT WITH RITUXIMAB    
time 0* time 1** time 2*** time 3**** time 4***** time 5****** 
Antibodies Jo-1 130 165 160 161 145 
SSA 114 110 105 103 100 100 
PaO2, mmHg 74 68 73 85 89 86 
PaCO2, mmHg 34 30 32 32 35 35 
DLCO, % pred. 80 22 31 35 42 52 
Krogh index 80 54,1 67 57 63 65 
FVC, % pred. 98 45 46 90 98 99 
FEV1, % pred. 90 50 52 80 90 90 
6MWT, m 600 75 150 450 500 500 
sPAP, mm Hg 35 35 35 33 33 32  
* Before treatment with rituximab. ** 1st course of rituximab administration. *** Interval between 1st and 2nd course of therapy with rituximab.
**** 2nd course of rituximab administration. ***** After 2nd course of therapy with rituximab. ****** Final medical examination.
Definitions of abbreviations: 6MWT, 6-minute walking test; DLCO, diffusing lung capacity for carbon monoxide; FEV1, forced expiratory volu-
me in 1 second; FVC, forced vital capacity; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; sPAP,

























e anti-sintetasi a localizzazione p
olm
onare
scribed in the literature are too few and have too
short a follow up to be able to predict the duration
of treatment efficacy and the possible need for fur-
ther doses of drug to standardize the treatment with
FIGURE 5: HIGH RESOLUTION CHEST CT SCAN TWO MONTHS AFTER THE SECOND TREATMENT WITH RITUXIMAB,
SHOWING RESIDUAL GROUND GLASS ATTENUATION AND ALMOST COMPLETE RESOLUTION OF FIBROTIC CHANGES































8 rituximab. In our case report only two cycles of ad-
ministration were required to block clinical and 
radiological manifestations of antibody-anti-
synthetase syndrome.
Further studies are also needed to identify possible
side effects of rituximab and the possible effects of
combination or interaction with other drugs. In our
study no adverse symptoms were revealed that
would have prevented continuing treatment.
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